Forecast

The analysts' average price target is +34,33€ (+8,36%). The median is +35,18€ (+11,05%).

Buy	14
Hold	1
Sell	0

News Go to news feed

Roivant Sciences shares reach record high at $37.06

Roivant Sciences shares rose to an all-time high of $37.06 and are currently trading at $37.14, with a market capitalization of $26.19 billion. The stock has gained 206.52% over 12 months and 66.82% year-to-date; however, analysts view the stock as overvalued according to InvestingPro. In the first fiscal quarter, adjusted loss per share was $0.26 (better than the expected -$0.30), but revenue of $1.44 million fell short of forecasts. TD Cowen raised its price target from $41 to $50 and reiterated a "Buy" rating, citing potential catalysts in the second half of the year. » More on de.investing.com
Roivant Sciences: investment three years ago would have returned about 195%

Three years ago Roivant Sciences traded at $11.50. A $10,000 investment would now be worth about $29,487 at a share price of $33.91, an increase of 194.87%. The company is valued at roughly $24.50 billion on the market; calculation does not account for stock splits or dividends. » More on finanzen.net
Roivant Sciences: $10,000 investment five years ago now up 262.97%

A $10,000 investment in Roivant Sciences at the closing price on 13 July 2021 ($9.91) would have grown to $36,296.67 by 10 July 2026, based on a price of $35.97 per share and a performance of +262.97%. The company is recently reported to have a market capitalization of $25.92 billion. The calculation does not account for stock splits or dividends. » More on finanzen.net

Financials

In the last quarter, Roivant Sciences had revenue of 1.26m€ and net profit of −166.33m€

(EUR)	Jun 2026	YoY
Revenue	+1.26m	31,37%
Gross profit	+1.01m	40,68%
Net profit	−166.33m	12,23%
EBITDA	−252.59m	11,02%

Fundamentals

Metric	Value
Market capitalization	+22.59b€
Number of shares	722.41m
52-week high/low	+32,58€ - +9,97€
Dividends	No
Beta	1,13
P/E ratio	−95,88
PEG ratio	+0,80
P/B ratio	+6,21
P/S ratio	+3.494,54

Company profile

Roivant Sciences Ltd. ist ein biopharmazeutisches und medizintechnisches Unternehmen, das Medikamente erforscht und entwickelt. Das Unternehmen entwickelt Produktkandidaten für die Behandlung verschiedener Therapeutika, darunter solide Tumore, Sichelzellerkrankungen, Hypophosphatasie, onkologische Malignome, Psoriasis, atopische Dermatitis, Vitiligo, Hyperhidrose, Akne, Myasthenia gravis, warme autoimmune hämolytische Anämie, Schilddrüsenerkrankungen, Sarkoidose und Staphylokokkenbakteriämie. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Sitz in London, Vereinigtes Königreich.